CAMBRIDGE, Mass., December 03, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...

Cognito Therapeutics is wrapping up the largest clinical trial ever conducted on a non-drug device for Alzheimer’s disease.

Cognito Therapeutics to Present New Data Highlighting Effects of Spectris™ on Lipid Transport Biomarkers in Alzheimer’s Disease at AAIC 2026 ...

Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...

Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics and West Virginia University’s ...

Cognito Therapeutics, a neurotechnology company birthed out of MIT, is pioneering breakthrough technology that may be able to slow the progression of Alzheimer’s and restore cognition. More than 55 ...

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, and Aetion, a global real-world ...

Cognito Therapeutics, a company using visual and auditory stimulation to treat neurodegenerative disorders, announced it closed an oversubscribed $105 million Series C funding round. Morningside ...

For decades, biotech companies have struggled to develop treatments for Alzheimer's disease, a disorder that causes loss of memory and other mental functions and affects roughly 6.5 million Americans.

In a sea of failed Alzheimer’s treatments, a digital health startup is hoping to find answers in a noninvasive treatment using light and sound. Cognito was founded by MIT Professors Li-Huei Tsai and ...